Black Canyon Bio
Developer of precision cancer immunotherapies based on a specific neoantigen-targeted peptide technology platform. The organization focuses on discovery and credentialing of tumor neoantigens, preclinical and translational development, early-phase clinical advancement of peptide vaccine candidates, biomarker qualification, and supporting regulatory and commercial activities to advance therapies for solid tumors and virus-associated cancers.
Industries
N/A
Products
Peptide cancer vaccine candidate for virus-associated cancers (lead program)
A peptide-based cancer vaccine candidate targeting neoantigens associated with virus-linked tumors. Identified as the lead program with planned clinical testing in 2026.
Specific neoantigen peptide technology platform
Platform technology enabling identification and credentialing of tumor-specific neoantigens to support personalized peptide vaccine development.
Peptide cancer vaccine candidate for virus-associated cancers (lead program)
A peptide-based cancer vaccine candidate targeting neoantigens associated with virus-linked tumors. Identified as the lead program with planned clinical testing in 2026.
Specific neoantigen peptide technology platform
Platform technology enabling identification and credentialing of tumor-specific neoantigens to support personalized peptide vaccine development.
Services
Translational R&D and preclinical program development
Management and execution of translational research and preclinical studies to advance therapeutic candidates toward clinical entry.
Biomarker qualification and assay validation
Qualification and validation of biomarkers and pharmacodynamic assays for incorporation into clinical protocols.
Regulatory documentation and strategy support
Preparation of regulatory documentation and support for regulatory affairs including FDA submission materials.
Business development and fundraising advisory
Advisory services for corporate finance, fundraising, strategic partnerships and transaction due diligence.
Translational R&D and preclinical program development
Management and execution of translational research and preclinical studies to advance therapeutic candidates toward clinical entry.
Biomarker qualification and assay validation
Qualification and validation of biomarkers and pharmacodynamic assays for incorporation into clinical protocols.
Regulatory documentation and strategy support
Preparation of regulatory documentation and support for regulatory affairs including FDA submission materials.
Business development and fundraising advisory
Advisory services for corporate finance, fundraising, strategic partnerships and transaction due diligence.
Expertise Areas
- Neoantigen vaccine development
- Translational and preclinical development
- Early-phase clinical development
- Biomarker discovery and qualification
Key Technologies
- Neoantigen-targeted peptide vaccines
- Peptide design and synthesis
- Bioinformatics for antigen identification
- Molecular engineering